# N4 Pharma broker offer to raise a maximum of £1 million

- Link: https://www.directorstalkinterviews.com/n4-pharma-broker-offer-to-raise-a-maximum-of-1-million/4121090962
- Published: 2022-11-18T07:05:59+00:00
- Author: Giles

* N4 Pharma (LON:N4P) has announced a Broker Offer through Turner Pope Investments(
   TPI) Limited (“TPI”)

 * The Issue Price of the Broker Offer is 2 pence per new ordinary share

 * Existing Shareholders or other interested parties who wish to register their 
   interest in participating in the Broker Offer should click on the following TPI
   platform link: [N4 Pharma Broker Offer](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.office.com%2Fr%2FT1NwuLTc7b&data=05%7C01%7CAndy.Thacker%40TurnerPope.com%7C4f2cd6e21a26487666d108dac896f44f%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638042847908576330%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=ZTwQMELPoVJRhmFZwYB6Q4ViTnJPTGPnKcyMqUTybQk%3D&reserved=0)

 * The Broker Offer has an initial expected value of £0.25 million but may be extended,
   with the express agreement of the Company, to £1.0 million in the event the Broker
   Offer is oversubscribed

 * All bids communicated to TPI under the Broker Offer are subject to review and
   acceptance by the Company and TPI and priority will be given to existing shareholders
   in the event of oversubscription

 * The Broker Offer remains open until 4:30 p.m. on Monday, 21 November 2022

**Broker Offer through TPI**

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, wishes to provide
an opportunity for shareholders and other investors who did not participate in the
fundraising announced today to invest in the Company.

Under the Placing Agreement, TPI has been granted an option in the form of a broker
offer under which TPI will, as agent for the Company, invite subscriptions for additional
new ordinary shares of 0.4p each in the Company with an initial expected value of
£0.25 million at the issue price of 2p.  The Broker Offer may be extended, with 
the express agreement of the Company, to £1.0 million in the event the Broker Offer
is oversubscribed.  Accordingly, the maximum number of Broker Offer Shares to be
issued under the Broker Offer at the Issue Price is 50,000,000.

The Broker Offer opens immediately and will close at 4.30pm on Monday, 21 November
2022.

As far as is practical, participation in the Broker Offer will be prioritised for
shareholders (direct or indirect) on the register at the close of business on 17
November 2022 (“Existing Shareholders”). 

To subscribe for Broker Offer Shares, Existing Shareholders or other interested 
parties who wish to register their interest in participating in the Broker Offer
should click on the following link : [N4 Pharma Broker Offer](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.office.com%2Fr%2FT1NwuLTc7b&data=05%7C01%7CAndy.Thacker%40TurnerPope.com%7C4f2cd6e21a26487666d108dac896f44f%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638042847908576330%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=ZTwQMELPoVJRhmFZwYB6Q4ViTnJPTGPnKcyMqUTybQk%3D&reserved=0)

A further announcement will be made following the end of the period during which
the Broker Offer is open.  If the Broker Offer is not fully subscribed by 4.30 p.
m. on 21 November 2022, orders from eligible investors will be satisfied in full,
and the balance of the Broker Offer shall lapse.

Share on:
